# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Franklin D. Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET002-SYN
- Date: 2026-03-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Brooks, MD
- Calendar frame: modern shifted

## Reason for visit

Primary care visit for breathlessness, orthopnea, and leg swelling. **S**

## Historical basis

- Franklin Delano Roosevelt was born on January 30, 1882, at Springwood, the family's estate in Hyde Park, New York. **D**
- In the summer of 1921 Roosevelt developed a paralytic illness at Campobello; on August 25, 1921, Dr. Robert Lovett diagnosed infantile paralysis (polio), and Roosevelt remained paraplegic, using leg braces from early 1922. **D**
- A 2003 Bayesian analysis of the recorded symptoms concluded that Guillain-Barré syndrome was more probable than paralytic polio as the cause of Roosevelt's 1921 illness; the conclusion is disputed and cannot be confirmed because no cerebrospinal fluid was examined. **R**
- In May 1941 Roosevelt had severe iron deficiency anemia, with hemoglobin reported at 4.5 g/100 mL. **D**
- At an examination at Bethesda Naval Hospital on March 27, 1944, Roosevelt's blood pressure was 186/108; he was breathless and cyanotic with rales, and X-rays and an electrocardiogram showed an enlarged heart, congestive heart failure, and a mitral murmur. His blood pressure had not been checked since February 27, 1941. **D**
- After the March 1944 examination Roosevelt was treated with digitalis, a low-sodium and weight-reduction diet, and rest; his working hours were reduced, his cigarettes were limited to ten a day, and his evening cocktails were reduced. **D**
- Roosevelt's father, James Roosevelt, died in 1900 during Franklin's first term at Harvard; his mother, Sara Delano Roosevelt, died at Springwood in September 1941. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Breathlessness, poor sleep from orthopnea, and leg swelling are cutting short his workdays. **S**
- Wants to stop smoking without losing his edge at work. **S**

## Strengths and supports

- Supports: spouse, an adult daughter who encouraged this visit, and close staff **S**

## Medications and allergies

- Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily **S**
- Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Nicotine 21 mg/24 hr transdermal patch, apply one patch daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- August 25, 1921: Paralytic illness in August 1921, diagnosed at the time as infantile paralysis (polio); paraplegic thereafter, with leg braces from early 1922 **D** (CLM-0003)
- Proposed in 2003 about the 1921 illness: Guillain-Barré syndrome proposed retrospectively as the cause of the 1921 paralysis; disputed **R** (CLM-0004)
- May 1941: Severe iron deficiency anemia in May 1941, hemoglobin reported at 4.5 g/100 mL **D** (CLM-0005)

## Procedures and immunizations

- No procedures before this visit. **S**
- 2025-10-14: Influenza vaccine, 2025-2026 season **S**
- 2021-05-03: Tdap vaccine **S**

## Family history

- father: Died in 1900; cause not recorded in the cited source **D** (CLM-0009)
- mother: Died in September 1941; cause not recorded in the cited source **D** (CLM-0009)

## Measurements

NT-proBNP: 2850 pg/mL (high); Sodium: 137 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 1.18 mg/dL; eGFR: 70 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Hemoglobin: 12.6 g/dL (low); Ferritin: 48 ng/mL; Transferrin saturation: 16% (low); TSH: 2.1 mIU/L; LDL cholesterol: 132 mg/dL (high); HbA1c: 5.9% (high); Urine albumin-creatinine ratio: 64 mg/g (high); KCCQ-12 overall summary: 38; PHQ-2: 1. All results are synthetic.

BP 186/108 mmHg; pulse 96 bpm; respirations 22/min; temperature 36.9 °C; oxygen saturation 93% on room air; weight 88 kg; BMI 24.9 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, fully oriented, and good-humored; tends to minimize symptoms; Mood euthymic; PHQ-2 negative. Functional status: Uses a manual wheelchair since a paralytic illness at age 39; independent in transfers and upper-body activities of daily living; Breathless after propelling the wheelchair short distances and when lying flat; NYHA class III at intake. Physical examination is intentionally limited. **S**

## Assessment

1. Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findings; status draft. **S**
2. Heart failure with reduced ejection fraction, NYHA class III at diagnosis; status draft. **S**
3. Nicotine dependence, cigarettes; status draft. **S**
4. Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed; status draft. **S**
5. Prediabetes; status draft. **S**
6. Hyperlipidemia; status draft. **S**

## Plan

- Start guideline-directed therapy for HFrEF: sacubitril/valsartan, carvedilol, and empagliflozin, with furosemide for congestion; add spironolactone after the two-week potassium check. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**
- Check a basic metabolic panel one to two weeks after each renin-angiotensin or mineralocorticoid antagonist change, then every three to six months when stable. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026) **S**
- Treat to a blood pressure below 130/80 with home blood pressure and daily weight logs; low-sodium diet. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026) **S**
- Tobacco cessation counseling with nicotine replacement and a quit date. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
- Cardiology referral to confirm the diagnosis, review the echocardiogram, and guide titration. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
